论文部分内容阅读
目的探究慢性心力衰竭(心衰)患者心脏再同步化治疗(CRT)治疗前后血清N末端脑利钠肽前体(NT-proBNP)、基质金属蛋白酶-9(MMP-9)水平变化及意义。方法 80例慢性心衰患者,随机分为观察组和对照组,各40例。对照组患者给予美托洛尔治疗,观察组患者给予CRT外加卡维地洛治疗。比较两组患者治疗前后血清NT-proBNP、MMP-9水平变化情况。结果治疗前,两组患者血清NT-proBNP、MMP-9水平比较差异无统计学意义(P>0.05);治疗后,观察组患者血清NT-proBNP为(327.4±201.9)pg/ml、MMP-9为(46.8±8.7)pg/ml,均低于对照组的(521.7±86.9)、(78.5±11.2)pg/ml,差异具有统计学意义(P<0.05)。结论血清NT-proBNP、MMP-9水平的变化情况可以作为慢性心衰病情发展的指向标,以及CRT临床治疗效果的深化指标,对慢性心衰患者的临床治疗具有重要的指导价值。
Objective To investigate the changes of serum N-terminal pro brain natriuretic peptide (NT-proBNP) and matrix metalloproteinase-9 (MMP-9) levels in patients with chronic heart failure (CHF) before and after cardiac resynchronization therapy (CRT) Methods Eighty patients with chronic heart failure were randomly divided into observation group and control group, 40 cases each. Patients in the control group were treated with metoprolol, and patients in the observation group were given CRT plus carvedilol. The changes of serum NT-proBNP and MMP-9 levels in two groups before and after treatment were compared. Results Before treatment, the serum levels of NT-proBNP and MMP-9 in the two groups had no significant difference (P> 0.05). After treatment, the serum NT-proBNP in the observation group was (327.4 ± 201.9) pg / 9 were (46.8 ± 8.7) pg / ml, which were lower than those of the control group (521.7 ± 86.9) and (78.5 ± 11.2) pg / ml, respectively. The difference was statistically significant (P <0.05). Conclusion The changes of serum NT-proBNP and MMP-9 levels can be used as a guideline for the development of chronic heart failure, and the further indicators of the clinical effect of CRT. It has an important guiding value for the clinical treatment of patients with chronic heart failure.